Montreal-based enGene has lined up $11.5 million in venture financing to put its next-gen approach to an inflammatory bowel disease treatment through its first clinical test.
Medical device giant Medtronic said it reached another milestone in developing an artificial pancreas with the completion of global evaluations of its new insulin delivery system.
Bind Therapeutics believes its lead nanoparticle treatment can make a difference for a subgroup of lung cancer patients, pointing to some positive results from an otherwise mixed mid-stage trial as it prepares for further study.
Billing it as the most important new innovation in the interferon drug class in a decade, Biogen Idec nailed down the FDA's approval of Plegridy, a new multiple sclerosis drug that patients can easily inject themselves with once every two weeks.
Shares of AcelRx took a painful 30% plunge on Monday morning as investors got a chance to respond to the biotech's announcement late Friday night that the FDA had rejected its application for Zalviso, its sufentanil sublingual microtablet drug/device system for fighting pain.
San Diego biotech Otonomy isn't biding its time, filing to go public in an $86.3 million IPO just three days after unveiling positive Phase III results for its lead drug.
Aprecia has an MIT-licensed method of 3-D printing pills and a plan to hit the market with easy-to-take formulations of top-selling medicines. To get there, the biotech has tapped CRO inVentiv Health, which is on hand to lend its commercialization expertise.
Baxter is buying out collaborator Chatham Therapeutics for $70 million, planning to absorb the gene therapy specialist into its growing hemophilia R&D operation as it prepares to separate its drug and device businesses next year.
After two FDA rejections, MannKind has returned with more data on its long-delayed inhaled diabetes drug, but regulators see Afrezza as anything but a slam-dunk case, raising questions over the treatment's safety and efficacy before a scheduled review.
Switzerland's Molecular Partners is convinced that it has created a better delivery vehicle for cancer drugs, and Roche is promising to pay up to a billion dollars-plus to see if they're right.